Nataliia Maksymovych

Nataliia Maksymovych

Auto-generated profile, based on publicly available information

Nataliia Maksymovych

Львівський національний медичний університет імені Данила Галицького

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
OZO. M. Zaliska
O. M. Zaliska
OSO. M. Semenov
O. M. Semenov
NMN. M. Maksymovych
N. M. Maksymovych
MSM. V. Slabyy
M. V. Slabyy
BZB. M. Zalisky
B. M. Zalisky
IMI. H. Mudrak
I. H. Mudrak
The pharmacist as a member of the medical team is responsible for the life and health of the population in the context of the COVID-19 pandemic in accordance with the recommendations of WHO and FIP, 2020. According to the WHO, 82% of patients with COVID-19 are treated by a family doctors and receive pharmaceutical care at the nearest pharmacies, but this can lead to unwanted contact between infected and healthy people, as well as contact with a pharmacist when dispensing drugs, which can lead to COVID-19 infection. Compliance with quarantine measures in accordance with the Resolutions of the Cabinet of Ministers and Orders of the Ministry of Health of Ukraine in pharmacies is an important component of overall safety during a pandemic, and the role of pharmacists in preventing the COVID-19 pandemic is important. The aim of this study was to conduct an expert evaluation of the effectiveness of quarantine measures due to the orders of the Ministry of Health of Ukraine in pharmacies. The sample of 586 experts included pharmacists, heads of pharmacies in 6 regions of Ukraine: Lviv, Vinnytsia, Ivano-Frankivsk, Zakarpattia, Khmelnytsky, Chernivtsi. According to a specially developed questionnaire «Assessment of the effectiveness of quarantine measures in the pharmacy at COVID-19» pharmacists were interviewed during March-October 2020. Methods of face-to-face questionnaires, interviews with the help of information and communication technologies, methods of generalization and systematization are used. According to the results of the analysis of 586 questionnaires, the respondents were ranked according to the parameters: specialty, work experience, qualification category. It was found that in 97.5% of pharmacies quarantine measures were implemented in March, in 2.5% pharmacies were in April 2020. The results of the pharmacists' survey show that the most effective quarantine measures are: wearing a protective mask (99.0%), washing hands and using disinfectants (97.0%), maintaining a social distance between visitors and pharmacy staff, as well as visitors to each other 1.5 m (94.5%), washingof pharmacy surfaces and floors with disinfectant solutions (91.0%), ventilation of pharmacy rooms (89.5%). Systematization of these questionnaires showed that 100% of pharmacists consider it necessary and prospective the approval by Ministry of Health of Ukraine a separate «Protocol of the pharmacist for the release of medicines and medical devices for the treatment of uncomplicated forms of coronavirus infection COVID-19» to optimize pharmaceutical care. Pharmacist as member of the medical team during the COVID-19 pandemic should conduct educational work among the population to prevent the spread of the COVID-19 pandemic.

9 July 2020 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
VHV. S. Huz
V. S. Huz
OZO. M. Zaliska
O. M. Zaliska
NMN. M. Maksymovych
N. M. Maksymovych
Improving access and affordability for patients of essential drugs in the treatment of cardiovascular diseases is a priority because mortality and a morbidity rates are high in Ukraine. In April 2017, the government launched the reimbursement program «Affordable medicines», which included drugs to treat cardiovascular disease. The aim of the study was a retrospective analysis of released prescriptions on the example of the pharmacy № 1 in Vynohradiv, Transcarpathian region, which serves patients from the city and Vynohradiv district, which allowed us to analyze and compare the structure of the appointments of primary care physicians and to identify the main INN, stocks of which should be a priority in pharmacies for the treatment of cardiovascular diseases. The objects of study were the records of the pharmacies about drugs released in the program for 24 months, the Orders of the Ministry of Health of Ukraine, the CMU Decisions, the Drug Registry for cardiovascular diseases, the cost for reimbursement in the program «Affordable Medicines» as well. Frequency analysis methods, ATC/DDD methodology, as well as methods of comparative, logical and content analysis were used. Data for the selected period were analyzed using frequency analysis methods and ATC/DDD method, and it was found that enalapril, spironolactone and clopidogrel were in the lead. It was found that the majority of patients in 2017 chose free drugs (more than 80%), and in 2018–2019 this rate was only 60%. According to prescriptions, about 92% are patients from Vynohradiv district, which confirms the improvement of access to drugs in the program «Affordable Medicines» for the rural population. The results were verified by comparing the released e-prescriptions for cardiovascular diseases in the city and district and found that the structure of prescriptions for cardiovascular diseases on e-prescriptions from April 2019 to April 2020 remains stable and the main share is 4 INN: clopidogrel, enalapril, amlodipine and bisoprolol. It is determined that in order for the «Affordable Medicines» program, the provision and convenience of patients, the pharmacies need to have an expanded list of trade names and a sufficient supply of enalapril, spironolactone, clopidogrel and bisoprolol.

17 February 2022 in Фармацевтичний часопис
Verified
Journal Article
Open access
PDF file
VHV. S. Huz
V. S. Huz
OZO. M. Zaliska
O. M. Zaliska
NMN. M. Maksymovych
N. M. Maksymovych
Мета роботи. Провести аналіз упровадження урядової програми реімбурсації «Доступні ліки» для амбулаторного лікування основними лікарськими засобами пацієнтів із серцево-судинними захворюваннями, цукровим діабетом 2 типу та бронхіальною астмою за 2019–2020 роки. Матеріали  і  методи. Об’єктами дослідження були дані з НСЗУ за 2019–2020 роки, а також Постанови КМУ, Накази МОЗ України про затвердження Реєстру лікарських засобів, вартість яких підлягає відшкодуванню у програмі «Доступні ліки». У дослідженні було використано методи частотного, порівняльного, логічного та контент-аналізу. Результати  й  обговорення. Розроблено методику аналізу програми реімбурсації з урахуванням районування території України за 5 макрорегіонами та проведено аналіз таких показників, як: бюджетне фінансування програми; кількість виписаних та відпущених електронних рецептів з 01 квітня 2019 року; розподіл електронних рецептів у програмі за віком та статтю пацієнтів; структура аптек за формою власності та типом населеного пункту. Виявлено, що обсяг бюджетного фінансування програми «Доступні ліки» у 2020 році зріс у 3 рази порівняно з 2017 роком. Кількість аптек у 2020 році зросла в 1,84 раза порівняно зі стартом програми. Більшість залучених до програми аптек розташована в містах Західного та Центрального макрорегіону. Встановлено, що у 2020 році найвищі темпи приросту, за досліджуваними параметрами, зафіксовані у Південному та Західному макрорегіонах країни. Впродовж 2019–2020 років понад 50 % е-рецептів було виписано на такі міжнародні непатентовані назви (МНН): бісопролол, клопідогрель, еналаприл та амлодипін. Висновки. Проведений аналіз програми реімбурсації виявив збільшення кількості аптек у 1,84 раза порівняно зі стартом програми у 2017 році. Згідно з регіональним розподілом та аналізом показників, найвищі показники приросту встановлені у Південному макрорегіоні. За досліджуваний період більше 50 % з усіх е-рецептів для лікування АГ було виписано для таких лікарських засобів як: бісопролол, клопідогрель, еналаприл та амлодипін.

30 December 2015 in Journal of Health Policy & Outcomes Research
Verified
Journal Article
Closed access
OZOlha Zaliska
Olha Zaliska
NMNataliia Maksymovych
Nataliia Maksymovych
OSOrest Sichkoriz
Orest Sichkoriz
VTViacheslav Tolubaiev
Viacheslav Tolubaiev

30 July 2020 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
OZO. M. Zaliska
O. M. Zaliska
КSК.-О. Ya. Stasiv
К.-О. Ya. Stasiv
NMN. M. Maksymovych
N. M. Maksymovych
In Ukraine, in order to achieve the Sustainable Development Goals, the State Strategy for the Implementation of the State Policy for the Provision of the Population with Medicines for the Period until 2025 has been approved, which includes improving the availability of drugs to improve the quality of life. Assisted Reproductive Technologies (ART) are gaining widespread implementation and funding from the budget in the world. Goal – the aim of the work was to analyze the state and dynamics of ART cycles in Ukraine for 1999–2019 and to estimate the cost of ART in Ukraine and to develop a methodology for estimating the availability of ART and comparison with European countries. Materials – international and domestic publications on the assessment of the availability of drugs, the cost of ART. Research methods: system analysis, data synthesis and generalization of information, webometric analysis, statistical analysis of data on the number of ART cycles for 1999-2018, analysis of ART costs. It is determined that the indicator of the number of ART cycles per 1 million population increased 29.9 times for 1999–2018, which is due to the increase in the number of ART centers conducted ART cycles in relation to the decrease in the population of Ukraine. It was found that 85% of ART centers are concentrated in only 4 cities (Kyiv, Lviv, Odessa, Kharkiv), which reduces the accessibility of the population to ART cycles, especially in the conditions of quarantine and pandemic COVID-19. It was found that in 1999–2018 the number of ART centers increased 7.7 times, but only 10.8% of ART centers have state funding, which indicates the low availability of ART for budget funds. It was found that the structure of ART cycles changed significantly. The average costs for the most common ART cycles IVF and ICSI in Ukraine as of the end of 2019 have been determined. It has been shown that only 26% of ART centers provide information on the cost of ART cycles, and web pages need to be filled with information on the cost of ART cycles to ensure that patients are properly informed. It is shown that in Ukraine as of 2020 the costs of ART cycles are 24 425–30 516 UAH (917,25–1 010,57 Euro) depending on the type of cycle from the perspective of the payer. It is estimated that the availability of ART is 1.5–9.98 depending on the type of ART cycle, the cost of ART cycles is 6–10 times higher than the average family income, when in European countries the availability of ART is much lower 1,5–4.2, which showed higher availability of ART in European countries from payer prospect.

1 May 2020 in Value in Health
Verified
Journal Article
Closed access
NMN. Maksymovych
N. Maksymovych
OZO. Zaliska
O. Zaliska
VHV. Huz
V. Huz
OBO. Brezden
O. Brezden
ASAdriana Solovei
Adriana Solovei
ZZZ. Zabolotnya
Z. Zabolotnya